Bliss GVS Pharma: Should You Buy, Hold, or Sell Right Now?
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Market
Bliss GVS Pharma share price Rs 700.95 (NSE), down over 3% today, near its 52-week high. 52-week range Rs 118 to Rs 729.90. Q1 FY27 profit up 15.8% YoY.
Quick Answer
Bliss GVS Pharma Ltd share price is trading around Rs 701, down more than 3 percent today, close to its 52-week high of Rs 729.90 and nearly six times its 52-week low of Rs 118. Q1 FY27 revenue grew 21.5 percent year on year to Rs 295.18 crore, with net profit up 15.8 percent to Rs 51.37 crore from Rs 44.36 crore, continuing a consistent, accelerating trend across recent quarters. Full-year FY26 revenue grew 18.2 percent with profit up 49.3 percent to Rs 134.73 crore from Rs 90.26 crore in FY25. The stock trades at a premium of 54.40 times earnings against the pharmaceutical sector average near 38 times.
Bliss GVS Pharma share price is down more than 3 percent today, trading around Rs 701 on the NSE, close to its 52-week high of Rs 729.90, nearly six times its 52-week low of Rs 118. With consistent, accelerating growth continuing in Q1 FY27, investors are asking whether this pharma formulations exporter is a stock to buy near its highs, a hold, or a sell.
This Bliss GVS Pharma stock analysis walks through the Q1 FY27 numbers, the very strong stock performance over the past year, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Bliss GVS Pharma
Before deciding on Bliss GVS Pharma share price, it helps to understand the underlying business. Bliss GVS Pharma Ltd. manufactures pharmaceutical formulations, including suppositories, serving domestic and export markets across multiple therapeutic segments.
As a pharma formulations exporter, Bliss GVS Pharma has delivered remarkably consistent, accelerating growth across recent quarters, with profit rising steadily from Rs 24.78 crore in December 2025 to Rs 51.37 crore in the most recent quarter, a pattern the stock’s very strong run over the past year reflects.
Bliss GVS Pharma Share Price Today: Key Levels
The table below summarises where Bliss GVS Pharma share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Bliss GVS Pharma CMP (NSE) | Rs 700.95 |
| Bliss GVS Pharma CMP (BSE) | Rs 704.55 |
| 52-Week High | Rs 729.90 |
| 52-Week Low | Rs 118.00 |
| Market Capitalisation | Approximately Rs 7,711 crore |
| Dividend Yield | 0.14% |
Bliss GVS Pharma share price is down today, though it remains close to its 52-week high, having risen nearly six-fold from its 52-week low, reflecting the market’s continued confidence in the company’s accelerating growth.
Check the Univest Screener for Live Stock Data
Bliss GVS Pharma Financial Performance
The Bliss GVS Pharma share price trend is closely tied to how these numbers evolve each quarter. Bliss GVS Pharma reported Q1 FY27 (June 2026 quarter) revenue of Rs 295.18 crore, up 21.5 percent year on year from Rs 242.92 crore, with net profit growing 15.8 percent year on year to Rs 51.37 crore from Rs 44.36 crore, continuing a consistent, accelerating quarterly trend: Rs 44.36 crore, Rs 28.59 crore, Rs 24.78 crore, Rs 37.00 crore, and now Rs 51.37 crore.
For the full year FY26, the company reported revenue of Rs 1,000.64 crore, up 18.2 percent year on year, with net profit of Rs 134.73 crore, up 49.3 percent from Rs 90.26 crore in FY25, confirming the growth trend has been sustained and accelerating across the full year.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 295.18 crore | Rs 51.37 crore | +21.5% revenue, +15.8% profit YoY |
| FY26 (full year) | Rs 1,000.64 crore | Rs 134.73 crore | +18.2% revenue, +49.3% profit YoY |
Valuation Check: Is Bliss GVS Pharma Share Price Expensive?
Any view on Bliss GVS Pharma share price should start from these valuation multiples. Bliss GVS Pharma share price currently reflects a price to earnings ratio of about 54.40 times trailing earnings, a premium to the broader pharmaceutical sector average of roughly 38 times. The price to book ratio stands near 6.5 times, supported by a strong 10.82 percent return on equity.
Debt to equity of 0.02 is very low. Given the consistently accelerating growth delivered across recent periods, this premium valuation reflects the market’s optimism about continued execution in the company’s pharma formulations and export business.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Bliss GVS Pharma share price. Bliss GVS Pharma share price is down more than 3 percent today, positioned close to its 52-week high of Rs 729.90, nearly six times its 52-week low of Rs 118, reflecting a very strong overall run over the past year. A stock trading this close to its high, backed by consistently accelerating growth, typically signals the market rewarding tangible execution, even as today’s pullback shows some profit-taking.
Trading volumes remain heavy, so investors should track Bliss GVS Pharma share price alongside continued export demand and formulation pipeline trends in coming quarters, rather than reacting to today’s single-day pullback at these technical levels.
Download the Univest iOS App or Univest Android App to track Bliss GVS Pharma’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Bliss GVS Pharma share price more than headline news on some sessions. Bliss GVS Pharma is a promoter-led pharma formulations and suppositories exporter with very low leverage. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Bliss GVS Pharma
- Remarkably consistent, accelerating growth: Profit has risen steadily over the past five quarters, from Rs 24.78 crore to Rs 51.37 crore, a truly rare and sustained improvement pattern.
- Very strong stock performance over the past year: The stock has risen nearly six-fold from its 52-week low, reflecting sustained investor confidence in the company’s accelerating growth.
- Very low financial leverage: A debt to equity ratio of just 0.02 gives the company significant financial flexibility.
Risks and Factors to Watch
- Rich valuation given the very strong run: A 54.40x PE, a premium to the pharmaceutical sector, following a nearly six-fold rise in the stock, leaves limited room for disappointment if growth slows from its currently strong pace.
- Pharma formulations export market competitive pressure: Bliss GVS Pharma competes against other domestic and international pharmaceutical formulations manufacturers, particularly in its suppositories and export niches.
- Today’s pullback from near the 52-week high: The stock is down more than 3 percent today after a very strong run, and investors should watch for confirmation of continued momentum rather than assuming the uptrend continues uninterrupted.
- Regulatory and export market compliance risk: As an exporter of pharmaceutical formulations, the company faces exposure to regulatory compliance requirements across its served international markets.
Bliss GVS Pharma Share Price Target: What the Data Suggests
Until then, Bliss GVS Pharma share price remains best tracked through live, verified data rather than a single fixed number. Bliss GVS Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering remarkably consistent, accelerating growth, trading at a premium to the pharmaceutical sector.
Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the rich valuation involved.
Bliss GVS Pharma: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Bliss GVS Pharma share price right now. The Bliss GVS Pharma buy or sell decision depends on whether this consistent growth can continue.
The case for buying: Investors who believe in Bliss GVS Pharma’s pharma export business and its consistently accelerating trend may find the current level worth considering despite today’s pullback from the 52-week high.
The case for holding: Existing shareholders who have benefited from the stock’s very strong run may prefer to stay invested while monitoring continued execution.
The case for waiting: Investors wanting a larger valuation cushion before committing fresh capital may prefer to wait for a more attractive entry point.
Historically, pharma exporters with consistent execution have rewarded patient investors, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Bliss GVS Pharma share price reflects a pharma formulations exporter delivering remarkably consistent, accelerating growth across recent quarters, trading close to its 52-week high at a premium to the pharmaceutical sector. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Bliss GVS Pharma a good stock to buy right now?
Ans. Bliss GVS Pharma has grown profit consistently over recent quarters, with Q1 FY27 profit up 15.8 percent year on year, continuing a trend also seen in FY26’s 49.3 percent annual profit growth. The stock trades at a premium to the pharmaceutical sector following a nearly six-fold rise from its 52-week low.
Q2. What is the Bliss GVS Pharma share price today?
Ans. Bliss GVS Pharma share price is trading around Rs 701 on the NSE, close to its 52-week high of Rs 729.90. The stock’s 52-week low is Rs 118.
Q3. What is the Bliss GVS Pharma share price target?
Ans. Bliss GVS Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser given the rich valuation involved.
Q4. What does Bliss GVS Pharma manufacture?
Ans. Bliss GVS Pharma manufactures pharmaceutical formulations, including suppositories, serving domestic and export markets across multiple therapeutic segments.
Q5. What is Bliss GVS Pharma’s market capitalisation and PE ratio?
Ans. Bliss GVS Pharma has a market capitalisation of approximately Rs 7,711 crore and trades at a price to earnings ratio of about 54.40 times, a premium to the pharmaceutical sector average PE of roughly 38 times.
Q6. How much has Bliss GVS Pharma’s stock risen over the past year?
Ans. Bliss GVS Pharma share price has risen nearly six-fold from its 52-week low of Rs 118, reflecting very strong investor confidence in the company’s consistently accelerating growth.
